Apoquel - 5.4mg - 100 pack

Aerosol spray containing oxytetracycline for use in cattle, sheep and pigs. Active ingredient: Oxytetracycline

A live vaccine against canine infectious tracheobronchitis caused by B. bronchiseptica and parainfluenza virus in dogs. Infectious tracheobronchitis is a highly contagious, multi-factorial disease of the dog’s respiratory tract. Bordetella bronchiseptica and canine parainfluenza are the most common bacterial and viral agents associated with the disease. Environmental factors such as stress, ventilation and climate may also contribute. Nobivac KC is a low volume dose (0.4ml), easy to administer, intranasal vaccine which acts against both the key causative agents of infectious tracheobronchitis and provides protection within 72 hours and lasts for at least 12 months. It can be used in puppies as young as three weeks and in pregnant bitches.

A combined live freeze-dried vaccine against canine distemper, infectious canine hepatitis, canine parvovirus and canine parainfluenza virus type 2. Each 1-ml dose of vaccine contains attenuated canine distemper virus, at least 104.0 CCID50, attenuated canine adenovirus (CAV2), at least 102.5 CCID50, attenuated canine parvovirus, at least 104.9 CCID50, attenuated canine parainfluenza type 2 virus, at least 104.7 CCID50 Uses Dogs and puppies from 8 weeks of age: Active immunization against distemper to reduce mortality and clinical signs; against infectious canine hepatitis to prevent clinical signs; against parvovirus to prevent clinical signs and reduce mortality and viral excretion; and against parainfluenza type 2 infections to reduce clinical signs and viral excretion. Onset of immunity: 2 weeks after completion of the primary vaccination course. Duration of immunity: 1 year. Dosage and administration Reconstitute the vaccine with Eurican L using a clean sterile syringe. Use the vaccine immediately after reconstitution of the freeze-dried pellet. Apply usual aseptic procedures. Use sterile and/or disinfectant-free equipment for injection purposes. Administer by subcutaneous injection. The following vaccination schedule is recommended: Primary vaccination: 1st injection: from 8th week of age. 2nd injection: 3 to 5 weeks later, from 12th week of age. Revaccination: Booster injections should be given annually thereafter.

Indications for use Active immunisation of dogs to: -prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae -prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola. -prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa. - prevent mortality, clinical signs, renal infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni.** Onset of immunity: 2 weeks after the second injection of the primary vaccination course for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains * For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity. ** For Leptospira Copenhageni the duration of immunity was not establishedIndications for use Active immunisation of dogs to: -prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae -prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola. -prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa. - prevent mortality, clinical signs, renal infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni.** Onset of immunity: 2 weeks after the second injection of the primary vaccination course for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains * For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity. ** For Leptospira Copenhageni the duration of immunity was not established